Published in Front Oncol on November 09, 2012
Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One (2014) 0.94
New tags for recombinant protein detection and O-glycosylation reporters. PLoS One (2014) 0.80
Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model. J Transl Med (2013) 0.78
Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. J Transl Med (2014) 0.76
A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. J Biol Chem (2016) 0.75
Anti-idiotype antibodies in cancer treatment. Front Oncol (2013) 0.75
Fine Mutational Analysis of 2B8 and 3H7 Tag Epitopes with Corresponding Specific Monoclonal Antibodies. Mol Cells (2016) 0.75
Single-chain antigen-binding proteins. Science (1988) 5.29
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 2.73
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 2.62
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood (2008) 2.50
Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol (1999) 2.25
DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med (1998) 1.83
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol (2006) 1.69
Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood (2010) 1.62
Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol (2000) 1.48
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol (1996) 1.43
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med (2000) 1.38
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol (2008) 1.35
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A (2008) 1.34
Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol (1987) 1.28
Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol (1997) 1.27
Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A (1996) 1.27
An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol (2002) 1.24
Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology (1989) 1.18
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer (2009) 1.17
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther (1998) 1.16
Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc Natl Acad Sci U S A (1992) 1.16
Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res (1991) 1.14
Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res (2006) 1.13
DNA immunization induces protective immunity against B-cell lymphoma. Nat Med (1996) 1.08
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood (2009) 1.08
An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release (2011) 1.07
Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol (1999) 1.07
Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol (2003) 1.07
Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther (2002) 1.05
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother (2006) 1.03
Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood (2004) 1.03
Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci U S A (2002) 1.02
Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med (1995) 1.02
Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol (2000) 1.01
Myeloma proteins as tumor-specific antigens. Transplant Proc (1975) 1.00
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol (1987) 0.98
A syngeneic idiotype is immunogenic when borne by IgM but tolerogenic when joined to IgG. Eur J Immunol (1995) 0.96
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol (1990) 0.96
Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol (1988) 0.96
Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther (2002) 0.95
Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol (2001) 0.95
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood (2007) 0.94
Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci U S A (1995) 0.94
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 0.93
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood (2009) 0.93
Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J Interferon Cytokine Res (2000) 0.92
Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol (1994) 0.92
Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng (1997) 0.92
DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 0.91
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res (1996) 0.91
A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A (2012) 0.91
Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica (2002) 0.90
A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol (1996) 0.90
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother (2011) 0.90
Anti-idiotype antibodies in cancer treatment. Oncogene (2007) 0.90
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol (2009) 0.89
Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res (2004) 0.89
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood (2001) 0.86
DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol (1999) 0.86
Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma. Crit Rev Immunol (2009) 0.85
Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants. Gene Ther (2001) 0.84
A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol (2000) 0.84
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother (2011) 0.84
Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter. Immunobiology (2005) 0.84
Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid Hybridomics (2003) 0.83
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother (2005) 0.83
Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. Blood (2012) 0.83
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol (2002) 0.83
Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Eur J Haematol (2011) 0.82
Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand J Immunol (2008) 0.82
Vaccination strategies in follicular lymphoma. Curr Hematol Malig Rep (2009) 0.81
Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer (2005) 0.81
A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Cancer Res (2006) 0.81
The primary IgM antibody repertoire: a source of potent idiotype immunogens. Eur J Immunol (2001) 0.81
Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol (2008) 0.81
Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther (2000) 0.81
Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice. Cell Immunol (2010) 0.81
The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma. Cancer Sci (2010) 0.81
Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol Immunother (2010) 0.81
Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer. Int J Breast Cancer (2011) 0.81
Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs (2011) 0.80
Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem (2005) 0.80
Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. Immunology (2006) 0.80
T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol (2008) 0.80
Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int J Cancer (2001) 0.79
Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner. Mol Immunol (2007) 0.79
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody. Cancer Immunol Immunother (2004) 0.79
DNA fusion vaccines enter the clinic. Cancer Immunol Immunother (2011) 0.79
Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin. Vaccine (2009) 0.79
Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. Int J Cancer (2004) 0.79
Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma (1995) 0.78
Characterization of rotavirus NSP2/NSP5 interactions and the dynamics of viroplasm formation. J Gen Virol (2004) 1.41
Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther (2007) 1.34
Rotavirus NSP5: mapping phosphorylation sites and kinase activation and viroplasm localization domains. J Virol (2002) 1.23
RNA interference of rotavirus segment 11 mRNA reveals the essential role of NSP5 in the virus replicative cycle. J Gen Virol (2005) 1.18
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Cdc42-mediated MTOC polarization in dendritic cells controls targeted delivery of cytokines at the immune synapse. J Exp Med (2010) 1.13
Uncoupling substrate and activation functions of rotavirus NSP5: phosphorylation of Ser-67 by casein kinase 1 is essential for hyperphosphorylation. Proc Natl Acad Sci U S A (2004) 1.12
Expression of Wiskott-Aldrich syndrome protein in dendritic cells regulates synapse formation and activation of naive CD8+ T cells. J Immunol (2008) 1.09
In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol (2008) 1.08
Impaired hyperphosphorylation of rotavirus NSP5 in cells depleted of casein kinase 1alpha is associated with the formation of viroplasms with altered morphology and a moderate decrease in virus replication. J Gen Virol (2007) 0.97
Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells. J Immunol (2008) 0.96
Evidence of CXC, CC and C chemokine production by lymphatic endothelial cells. Immunology (2003) 0.95
Effects of intrabodies specific for rotavirus NSP5 during the virus replicative cycle. J Gen Virol (2004) 0.93
Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. J Immunol (2005) 0.88
Selective targeting of proteins within secretory pathway for endoplasmic reticulum-associated degradation. J Biol Chem (2012) 0.87
Rotavirus viroplasm fusion and perinuclear localization are dynamic processes requiring stabilized microtubules. PLoS One (2012) 0.86
Rotavirus viroplasm proteins interact with the cellular SUMOylation system: implications for viroplasm-like structure formation. J Virol (2012) 0.86
Efficient detection of proteins retro-translocated from the ER to the cytosol by in vivo biotinylation. PLoS One (2011) 0.85
WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis (2007) 0.85
Efficient folding of the FcepsilonRI alpha-chain membrane-proximal domain D2 depends on the presence of the N-terminal domain D1. J Mol Biol (2002) 0.84
The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20. J Immunol (2006) 0.82
T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther (2007) 0.82
Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. J Virol (2013) 0.82
Design and selection of an intrabody library produced de-novo for the non-structural protein NSP5 of rotavirus. J Immunol Methods (2005) 0.81
Gangliosides, Ab1 and Ab2 antibodies IV. Dominance of VH domain in the induction of anti-idiotypic antibodies by gene gun immunization. Mol Immunol (2007) 0.81
CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules. J Biol Chem (2013) 0.81
Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner. Mol Immunol (2007) 0.79
Use of virus vectors for the expression in plants of active full-length and single chain anti-coronavirus antibodies. Biotechnol J (2006) 0.79
A minimal receptor-Ig chimera of human FcepsilonRI alpha-chain efficiently binds secretory and membrane IgE. Protein Eng (2002) 0.79
Binders based on dimerised immunoglobulin VH domains. J Mol Biol (2003) 0.79
Fusion of tags induces spurious phosphorylation of rotavirus NSP5. J Virol (2006) 0.79
An antibody derivative expressed from viral vectors passively immunizes pigs against transmissible gastroenteritis virus infection when supplied orally in crude plant extracts. Plant Biotechnol J (2006) 0.78
Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients. Biologicals (2013) 0.78
Recombinant dimeric small immunoproteins neutralize transmissible gastroenteritis virus infectivity efficiently in vitro and confer passive immunity in vivo. J Gen Virol (2007) 0.78
BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies. Cancer Immunol Immunother (2004) 0.78
Selection and characterisation of binders based on homodimerisation of immunoglobulin V(H) domains. FEBS Lett (2003) 0.77
Anti-idiotypic DNA vaccines for B-cell lymphoma therapy. Front Biosci (2002) 0.76
Specific recognition of a dsDNA sequence motif by an immunoglobulin VH homodimer. Protein Sci (2004) 0.75